Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05139368

Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer

RT-PACE: A Pilot Study of Adjuvant Hypo-Fractionated Radiotherapy for Non-Metastatic Cervical and Endometrial Cancer

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
22 (actual)
Sponsor
University of Utah · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This clinical trial studies the feasibility of using hypo-fractionated radiotherapy for the treatment of cervical or endometrial cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

Detailed description

PRIMARY OBJECTIVE: I. To establish the trial as feasible and to assess the impact upon acute gastrointestinal toxicity in the third week of pelvic radiotherapy following a hypo-fractionated schedule. SECODARY OBJECTIVES: I. To estimate impact upon acute urinary toxicity. II. To estimate impact upon patient reported gastrointestional toxicity. III. To assess acute quality of life following treatment. IV. To quantify acute financial toxicity following treatment. V. To assess satisfaction with decision-making following treatment. VI. To assess the overall survival throughout 3 years of post-treatment follow-up. OUTLINE: Patients undergo hypo-fractionated radiotherapy over 3 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 1, 3, and 6 months and then at 1, 2, and 3 years.

Conditions

Interventions

TypeNameDescription
RADIATIONHypofractionated Radiation TherapyUndergo hypofractionated radiation therapy

Timeline

Start date
2021-11-11
Primary completion
2024-07-17
Completion
2027-06-26
First posted
2021-12-01
Last updated
2024-11-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05139368. Inclusion in this directory is not an endorsement.